Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: A phase 2 trial Academic Article uri icon

Overview

MeSH Major

  • Cancer Vaccines
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Vaccines, Subunit

abstract

  • The current data suggested that vaccination-related transient disruption of immune tolerance may contribute to the reduction in Bcr-Abl transcripts. Clinically, this Bcr-Abl peptide vaccine may transiently improve the molecular response in a subset of patients with CML.

publication date

  • September 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5534348

Digital Object Identifier (DOI)

  • 10.1002/cncr.24468

PubMed ID

  • 19536894

Additional Document Info

start page

  • 3924

end page

  • 34

volume

  • 115

number

  • 17